A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Video providing an overview of the Grass Roots Innovation Program and how the activities support the next generation of life-science innovators and entrepreneurs
KDIGO’s 2024 Updated Guidelines Re-Emphasize Commitment to Comprehensive Testing for CKD
Mohamed Eid shares his thoughts on the updated KDIGO clinical practice guidelines, published in 2024, and the need for guidelines-directed care for CKD.
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.